CO2021008817A2 - Compuesto agonista de receptor thrβ y método de preparación y uso del mismo - Google Patents

Compuesto agonista de receptor thrβ y método de preparación y uso del mismo

Info

Publication number
CO2021008817A2
CO2021008817A2 CONC2021/0008817A CO2021008817A CO2021008817A2 CO 2021008817 A2 CO2021008817 A2 CO 2021008817A2 CO 2021008817 A CO2021008817 A CO 2021008817A CO 2021008817 A2 CO2021008817 A2 CO 2021008817A2
Authority
CO
Colombia
Prior art keywords
thrβ
preparation
receptor agonist
agonist compound
compound
Prior art date
Application number
CONC2021/0008817A
Other languages
English (en)
Inventor
Shanghai Yu
Ben Li
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of CO2021008817A2 publication Critical patent/CO2021008817A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe un compuesto representado por la siguiente fórmula (I) y una sal farmacéuticamente aceptable del mismo. El compuesto mejora la selectividad de THRα en tanto que mantiene buena actividad agonista de THRβ, mejorando de este modo las propiedades del fármaco terminado.
CONC2021/0008817A 2018-12-13 2021-07-02 Compuesto agonista de receptor thrβ y método de preparación y uso del mismo CO2021008817A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811527414.4A CN111320609A (zh) 2018-12-13 2018-12-13 一种THRβ受体激动剂化合物及其制备方法和用途
PCT/US2019/066013 WO2020123827A1 (en) 2018-12-13 2019-12-12 Thrβ receptor agonist compound and preparation method and use thereof

Publications (1)

Publication Number Publication Date
CO2021008817A2 true CO2021008817A2 (es) 2021-07-19

Family

ID=71071432

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008817A CO2021008817A2 (es) 2018-12-13 2021-07-02 Compuesto agonista de receptor thrβ y método de preparación y uso del mismo

Country Status (17)

Country Link
US (3) US11084802B2 (es)
EP (1) EP3893889A4 (es)
JP (1) JP2022512482A (es)
KR (1) KR20210102328A (es)
CN (3) CN111320609A (es)
AR (1) AR117694A1 (es)
AU (1) AU2019398339A1 (es)
BR (1) BR112021010871A2 (es)
CA (1) CA3120880A1 (es)
CL (1) CL2021001521A1 (es)
CO (1) CO2021008817A2 (es)
IL (2) IL283362B1 (es)
MA (1) MA54471A (es)
MX (1) MX2021006908A (es)
PE (1) PE20211788A1 (es)
SG (1) SG11202106194TA (es)
WO (1) WO2020123827A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018128393A (ru) 2012-09-17 2019-03-14 Мадригал Фармасьютикалз, Инк. Способ синтеза аналогов гормонов щитовидной железы и их полиморфов
EP3807267A4 (en) 2018-06-12 2022-03-16 Sichuan Haisco Pharmaceutical Co., Ltd. THYROID HORMONE RECEPTOR AGONISTS AND ASSOCIATED USES
EP3863635A4 (en) 2018-10-12 2022-06-15 Terns, Inc. THYROID HORMONE BETA RECEPTOR AGONIST COMPOUNDS
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
MA55890A (fr) 2019-05-08 2022-03-16 Aligos Therapeutics Inc Modulateurs de thr-beta et leurs procédés d'utilisation
CN111909137B (zh) * 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
WO2020239076A1 (zh) * 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
KR20230024277A (ko) * 2020-05-13 2023-02-20 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
CN116615416A (zh) 2020-08-25 2023-08-18 伊莱利利公司 Ssao抑制剂的多晶型物
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
CA3192169A1 (en) * 2020-09-17 2022-03-24 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
EP4232436A1 (en) * 2020-10-23 2023-08-30 Madrigal Pharmaceuticals, Inc. Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues
US11858913B2 (en) 2020-11-06 2024-01-02 Aligos Therapeutics, Inc. Bicyclic pyridazinones and methods of use thereof
CN116925045A (zh) * 2020-12-15 2023-10-24 中国科学院上海药物研究所 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN114685450A (zh) 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
AU2022228569A1 (en) * 2021-03-03 2023-10-12 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3238108A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-.beta. agonist
TW202327589A (zh) 2021-11-11 2023-07-16 美商拓臻製藥公司 肝病之組合療法
WO2023154842A1 (en) * 2022-02-10 2023-08-17 Madrigal Pharmaceuticals, Inc. Thr beta analogs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0377903A3 (de) * 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
WO2002051805A1 (de) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
WO2003064369A1 (fr) * 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
DK1919878T3 (da) * 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
AU2010240200B2 (en) 2009-04-20 2014-03-13 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
SG10201510307WA (en) 2011-11-14 2016-01-28 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102898377B (zh) * 2012-02-14 2016-01-20 南京圣和药业股份有限公司 一类酞嗪酮衍生物及其用途
EP3189046B1 (en) 2014-09-05 2020-08-26 Genentech, Inc. Therapeutic compounds and uses thereof
KR20190109387A (ko) * 2016-10-18 2019-09-25 마드리갈 파마슈티칼스, 인크. Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
EP3807267A4 (en) * 2018-06-12 2022-03-16 Sichuan Haisco Pharmaceutical Co., Ltd. THYROID HORMONE RECEPTOR AGONISTS AND ASSOCIATED USES
CN112601674A (zh) 2018-08-24 2021-04-02 全耐塑料高级创新研究公司 包括挡板和穿过该挡板的流体输送线的流体储箱用组件
CA3110520A1 (en) 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
AU2019359141A1 (en) 2018-10-12 2021-04-22 InventisBio Co., Ltd. Thyroid hormone receptor agonists
EP3863635A4 (en) 2018-10-12 2022-06-15 Terns, Inc. THYROID HORMONE BETA RECEPTOR AGONIST COMPOUNDS
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
WO2020169069A1 (en) 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
WO2020239076A1 (zh) 2019-05-29 2020-12-03 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Also Published As

Publication number Publication date
EP3893889A4 (en) 2022-08-03
CN113194958A (zh) 2021-07-30
US20200399249A1 (en) 2020-12-24
AU2019398339A1 (en) 2021-06-10
KR20210102328A (ko) 2021-08-19
PE20211788A1 (es) 2021-09-09
BR112021010871A2 (pt) 2021-08-31
US11084802B2 (en) 2021-08-10
CL2021001521A1 (es) 2022-01-28
MX2021006908A (es) 2021-07-07
US20230278988A1 (en) 2023-09-07
CN116444498A (zh) 2023-07-18
JP2022512482A (ja) 2022-02-04
US11034676B2 (en) 2021-06-15
AR117694A1 (es) 2021-08-25
US20200190064A1 (en) 2020-06-18
CA3120880A1 (en) 2020-06-18
IL283362A (en) 2021-07-29
CN111320609A (zh) 2020-06-23
CN113194958B (zh) 2023-05-23
EP3893889A1 (en) 2021-10-20
WO2020123827A1 (en) 2020-06-18
MA54471A (fr) 2021-10-20
IL283362B1 (en) 2024-03-01
SG11202106194TA (en) 2021-07-29
IL310699A (en) 2024-04-01
TW202039470A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
CO2021008817A2 (es) Compuesto agonista de receptor thrβ y método de preparación y uso del mismo
DOP2020000037A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
DOP2019000201A (es) Compuestos inhibidores del vih
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
UY35362A (es) Compuestos terapéuticos
EA201990833A1 (ru) Соединение пиридина
AR103680A1 (es) Inhibidores selectivos de bace1
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2020000376A1 (es) Compuesto pentacíclico.
MY197561A (en) Composition for increasing expression of pgc-1?
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
EA201692300A1 (ru) Производные карбоксамида
BR112021011325A2 (pt) Derivados de rapamicina
PH12019550154A1 (en) Azetidine derivative
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
AR111665A1 (es) Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp
BR112019006371A2 (pt) compostos, composições farmacêuticas, uso de um composto ou composição e kits